Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
At Faber, we’ve worked with 2,000+ clients in life science, healthcare IT, medical devices and engineering technology. We have over a dozen lawyers focusing their practices on handling these kinds of transactions, and our life science practice is among the deepest and most comprehensive in the country. As a result, whatever your opportunity, we’re likely to have a senior lawyer who has recently handled comparable deals involving similar technology, industry segments and client situations … very often with the same counterparties you’re talking to.
Further, many of our lawyers have worked in-house in your industry, giving them practical insight into how a contract will play out in the real world. Several of our professionals have been entrepreneurs and led venture-backed companies.
Our transactional experience includes:
At Faber, most of our attorneys have managed in-house legal departments for Big Pharma, where they launched such partnerships, then managed them throughout their life cycle. Several of us are former entrepreneurs whose business leadership resulted in successful collaborations.
A senior attorney will work closely with your scientific and business leaders to craft a strategic partnership that is “fit for purpose” — optimally designed to achieve your high priority R&D and commercial goals, while respecting your unique risk tolerance for key areas of business. We do this by considering whether each key term:
Because we appreciate that these deals are about forging business relationships, we understand where they can go wrong and how to negotiate terms that will help keep them on track. Based on our operational backgrounds, we’ll help you prioritize issues and account for the details that determine real world success.
We also have experience appropriately employing a wide variety of option based and staged deal structures.
Our clients rely on us to provide sound business judgment, as well as legal advice, to manage or mitigate specific risks and challenges in these structures, such as a change of control or shifts in business and scientific priorities during the full deal lifecycle.
Option for exclusive development and commercial rights to a suite of Paragon’s top-tier antibodies specifically engineered to target some of the largest and highest unmet needs in inflammatory and immunological conditions
Multi-year collaboration with AbCellera to discover therapeutic antibodies for multiple targets selected by Versant’s portfolio of biologics-focused biotechnology companies
License, Collaboration and Option Agreement to advance allogeneic CRISPR-Edited NK cell therapies, with milestones up to $920M per product plus royalties
Amended and Restatement of Research and Development Collaboration Agreement with GSK to identify and advance novel chemical entities for the potential treatment of TB as well as non-tuberculosis mycobacterial infections
United States gastrointestinal disease education and promotion agreement with Ironwood for Alnylam’s givosiran product
Exclusive license with Vir Biotechnology to develop and commercialize RNAi therapeutics for chronic hepatitis B virus (HBV) infection and a research collaboration for other infectious diseases
Cross-Licensing and Development Agreement for Bispecific Antibody Therapeutics in Immuno-oncology
Strategic Licensing Agreement for Next-Generation Gene Therapy Technologies
Discovery Collaboration Focused on Generation of Stem Cell Lines to Enable Development of Novel Therapeutics for Neurodegenerative Diseases
Strategic Research Collaboration for CAR T-cell Immunotherapeutics
Strategic Research Collaboration to Develop Treatments for Metabolic Diseases Utilizing Proprietary Antisense and RNAi Technologies (including $40 million in upfront payments, up to $871 million in milestone payments and royalties)
Research collaboration for autoimmune and chronic inflammatory disorders
Cross-license and cross-border strategic partnership to develop, manufacture and commercialize plasma-derived Inter-alpha Inhibitor Proteins (IAIPs) for treating orphan diseases and for other indications
Collaboration for the discovery and development of novel therapeutics for cancer using FMI’s genomics database
Drug discovery collaboration focused on kinase inhibitors for inflammatory disease
Collaboration for the development of drugs to combat Alzheimer’s and other neurodegenerative diseases (including amendment of a pre-existing license agreement with Harvard University)